慢性抗凝使用Xa因子抑制剂与维生素K拮抗剂患者外周血管介入治疗的结局比较
基于血管质量倡议-外周血管介入数据库分析109,268例患者,其中6,885例长期抗凝(FXaI 2,427例,VKA 4,458例)。VKA组围术期血肿率3.5% vs FXaI组1.9%(P<0.001),主要截肢率8.4% vs 6.7%(P=0.020),死亡率15.2% vs 7.6%(P≤0.001)。
要点
- VKA组主要截肢率8.4%高于FXaI组6.7%(P=0.020),死亡率15.2%高于FXaI组7.6%(P≤0.001)
核心结论
- 在接受PVI的PAD患者中,与VKA相比,FXaI慢性抗凝与更优的围术期和长期结局相关。
- 作者认为FXaI应作为PAD患者接受PVI时慢性抗凝的首选药物而非VKA。
研究设计与样本
- 基于血管质量倡议-外周血管介入数据库的对比分析,共分析109,268例患者,其中6,885例长期抗凝(FXaI组2,427例,VKA组4,458例)。
- 慢性抗凝定义为术前、出院时和长期随访中持续接受FXaI或VKA治疗的患者。
主要发现
- VKA组男性比例65.3%高于FXaI组61.0%(P<0.001),终末期肾病比例9.7%高于FXaI组4.6%(P<0.001),慢性肢体威胁性缺血治疗比例58.1%高于FXaI组52.7%(P<0.001)。
- VKA组PVI后血肿发生率3.5%高于FXaI组1.9%(P<0.001)。
- VKA组主要截肢率8.4%高于FXaI组6.7%(P=0.020),死亡率15.2%高于FXaI组7.6%(P≤0.001)。
临床怎么用
- 作者认为,对于接受PVI的PAD患者,FXaI应作为慢性抗凝的首选药物而非VKA。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients undergoing revascularization for peripheral arterial disease (PAD), low-dose Factor Xa inhibitors (FXaI) taken with aspirin improved limb and cardiovascular outcomes compared to aspirin alone. Furthermore, in atrial fibrillation and venous thromboembolism, FXaI are recommended over vitamin K antagonists (VKA) for chronic anticoagulation. While studies have evaluated different perioperative anticoagulation regimens in patients treated for PAD, the optimal regimen for chronic anticoagulation in patients with PAD undergoing peripheral vascular intervention (PVI) has not been determined. This analysis compares outcomes of patients after PVI that require chronic anticoagulation with FXaI and VKA. METHODS: The Vascular Quality Initiative-PVI database was used. Patients consistently treated with FXaI or VKA before the procedure, at discharge, and on long-term follow-up were defined as those receiving chronic anticoagulation. Patient demographics, procedural details, and perioperative and long-term outcomes were compared between FXaI and VKA groups. RESULTS: A total of 109,268 patients were analyzed, and 6,885 were chronically anticoagulated with FXaI (N = 2,427) or VKA (N = 4,458). Patients anticoagulated with VKA were more frequently males (65.3% vs. 61.0%, P < 0.001) with end-stage renal disease (9.7% vs. 4.6%, P < 0.001) and more likely to be treated for chronic limb-threatening ischemia (58.1% vs. 52.7%, P < 0.001). Rates of hematoma following PVI were significantly higher in patients taking VKA compared to FXaI (3.5% vs. 1.9%, P < 0.001). Multivariable logistic regression analysis showed that VKA were associated with increased perioperative hematoma than FXaI (odds ratio = 1.89 [1.30-2.82]). Compared to patients taking VKA, those receiving FXaI had lower rates of major amputation (6.7% vs. 8.4%, P = 0.020) and mortality (7.6% vs. 15.2%, P ≤ 0.001). Using Kaplan-Meier analysis, patients consistently anticoagulated with FXaI had improved amputation-free survival after PVI. Adjusting for significant patient and procedural characteristics, Cox proportional hazard regression demonstrated that there is an increased risk for major amputation or mortality in patients using VKA compared to FXaI (hazard ratio 1.61, [1.36-1.90]). CONCLUSIONS: Chronic anticoagulation with FXaI as compared to VKA was associated with superior perioperative and long-term outcomes in patients with PAD undergoing PVI. FXaI should be the preferred agents over VKA for chronic anticoagulation in patients with PAD undergoing PVI.
引用
- Huttler JJ, Alameddine D, Damara FA, et al. Comparative Outcomes of Peripheral Vascular Interventions in Patients on Chronic Anticoagulation with Factor Xa Inhibitors and Vitamin K Antagonists. Ann Vasc Surg. 2024. PMID: 38493886. doi:10.1016/j.avsg.2023.12.092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。